"Concerned" J&J hopes to stop monthly Tylenol recalls

The most recent recall of Children's Tylenol and related products is "a matter of great concern," writes Johnson & Johnson CEO Bill Weldon on a company blog. In a sustained GMP embarrassment, the late April recall marks the fourth such Tylenol action in as many months. It follows the mid-March move of quality VP Veronica Cruz to McNeil from J&J, and it precedes McNeil's hiring of independent quality experts. That's a lot of QC horsepower rolling into May, the fifth month; hopefully it will forestall a fifth Tylenol recall. Blog | Item

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.